TY - JOUR
T1 - An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma
T2 - NRG Oncology RTOG 0525 and 0825
AU - Gittleman, Haley
AU - Lim, Daniel
AU - Kattan, Michael W.
AU - Chakravarti, Arnab
AU - Gilbert, Mark R.
AU - Lassman, Andrew B.
AU - Lo, Simon S.
AU - MacHtay, Mitchell
AU - Sloan, Andrew E.
AU - Sulman, Erik P.
AU - Tian, Devin
AU - Vogelbaum, Michael A.
AU - Wang, Tony J.C.
AU - Penas-Prado, Marta
AU - Youssef, Emad
AU - Blumenthal, Deborah T.
AU - Zhang, Peixin
AU - Mehta, Minesh P.
AU - Barnholtz-Sloan, Jill S.
N1 - Publisher Copyright:
© 2017 The Author.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Background. Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram to estimate individualized survival probabilities for patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. Methods. This analysis included information on 799 (RTOG 0525) and 555 (RTOG 0825) eligible and randomized patients with newly diagnosed GBM and contained the following variables: age at diagnosis, race, gender, Karnofsky performance status (KPS), extent of resection, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and survival (in months). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using the 0525 data and were independently validated using the 0825 data. Models were internally validated using 10-fold cross-validation, and individually predicted 6-, 12-, and 24-month survival probabilities were generated to measure the predictive accuracy and calibration against the actual survival status. Results. A fnal nomogram was built using the Cox proportional hazards model. Factors that increased the probability of shorter survival included greater age at diagnosis, male gender, lower KPS, not having total resection, and unmethylated MGMT status. Conclusions. A nomogram that assesses individualized survival probabilities (6-, 12-, and 24-mo) for patients with newly diagnosed GBM could be useful to health care providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free software for implementing this nomogram is provided: http://cancer4.case.edu/rCalculator/rCalculator.html.
AB - Background. Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram to estimate individualized survival probabilities for patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. Methods. This analysis included information on 799 (RTOG 0525) and 555 (RTOG 0825) eligible and randomized patients with newly diagnosed GBM and contained the following variables: age at diagnosis, race, gender, Karnofsky performance status (KPS), extent of resection, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and survival (in months). Survival was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning analysis, with adjustment for known prognostic factors. The models were developed using the 0525 data and were independently validated using the 0825 data. Models were internally validated using 10-fold cross-validation, and individually predicted 6-, 12-, and 24-month survival probabilities were generated to measure the predictive accuracy and calibration against the actual survival status. Results. A fnal nomogram was built using the Cox proportional hazards model. Factors that increased the probability of shorter survival included greater age at diagnosis, male gender, lower KPS, not having total resection, and unmethylated MGMT status. Conclusions. A nomogram that assesses individualized survival probabilities (6-, 12-, and 24-mo) for patients with newly diagnosed GBM could be useful to health care providers for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free software for implementing this nomogram is provided: http://cancer4.case.edu/rCalculator/rCalculator.html.
UR - http://www.scopus.com/inward/record.url?scp=85019057047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019057047&partnerID=8YFLogxK
U2 - 10.1093/neuonc/now208
DO - 10.1093/neuonc/now208
M3 - Review article
C2 - 28453749
AN - SCOPUS:85019057047
SN - 1522-8517
VL - 19
SP - 669
EP - 677
JO - Neuro-oncology
JF - Neuro-oncology
IS - 5
ER -